Binhui Biotech

Wuhan Binhui Biotechnology updates its prospectus ahead of its planned listing on the Hong Kong Stock Exchange. The company, a biotechnology firm, prepares to enter public markets as part of its growth strategy. No further details on funding, products, or specific timelines are disclosed in the announcement.

Apr 2026LongbridgeNews article

Wuhan Bin Hui Biological Technology Co., Ltd. files for a listing on the Hong Kong Stock Exchange. The company engages Huatai International, China Merchants Securities International, and BOCI Asia Limited as joint sponsors for the process. The submission marks a key step toward potential public trading for the biotechnology firm.

Apr 2026LongbridgeNews article

Wuhan Binhui Biotechnology secures **breakthrough therapy designation** from China’s CDE for its **GM-CSF oncolytic herpes simplex virus type II (OH2)**. The treatment targets **unresectable or metastatic melanoma** in patients who have failed at least two standard therapies, including chemotherapy, immunotherapy, and targeted treatments. The CDE’s recognition accelerates clinical development for this viral-based cancer therapy.

Feb 2023Insight, China's Pharmaceutical IndustryNews article

Binhui Biopharm secures nearly **USD 47 million** in a Series B+ funding round. The biotech company specializes in oncolytic virus immuno-oncology, with its lead drug candidate **BS001 (OH2) injection**—a novel oncolytic virus therapy using **herpes simplex virus type II (HSV2)** as a carrier. The drug has received approval for clinical trials from **China’s NMPA** and the **U.S. FDA**.

Apr 2022EqualOceanNews article